Fenbendazole is available over the counter as a veterinary dewormer in the United States. You can buy it at pet stores, farm supply retailers, and online without a prescription. However, it has never been approved by the FDA for human use, and no human formulation exists.
What You Can Buy Without a Prescription
Fenbendazole is classified as an OTC animal drug by the FDA. It’s sold under brand names like Safe-Guard and Panacur, and you’ll find it in several forms designed for different animals. Panacur Paste 10%, for example, comes in oral syringes intended for horses, with each gram containing 100 mg of fenbendazole. Safe-Guard is sold as a liquid suspension and as granules commonly used for dogs, goats, and cattle. None of these products require a veterinary prescription to purchase.
You’ll typically find these products at stores like Tractor Supply, PetSmart, Chewy, and Amazon. Prices vary but generally range from $10 to $30 depending on the form and quantity. The ease of access is a major reason fenbendazole has gained attention online for off-label human use, particularly after viral claims about its potential role in cancer treatment.
Why It’s Not Approved for Humans
Despite being easy to buy, fenbendazole has no approved human dose, no standardized human formulation, and no established monitoring framework. The FDA, the European Medicines Agency, and Australia’s Therapeutic Goods Administration have all declined to approve it for people. Its safety profile in humans has never been formally documented in medical literature, which means the basic questions about how much the body absorbs, how long it stays in the system, and what side effects occur at various doses remain largely unanswered in a clinical setting.
Product quality also varies widely across veterinary and supplement sources. Because these products are manufactured to animal drug standards, they aren’t held to the same purity, consistency, or labeling requirements as human pharmaceuticals. Two products with the same listed concentration could differ meaningfully in what they actually deliver.
How It Compares to Mebendazole
Fenbendazole belongs to a family of drugs called benzimidazoles. Its close chemical cousin, mebendazole, is FDA-approved for treating certain intestinal worm infections in humans. The two drugs work through a similar mechanism, which is part of why people have drawn connections between them. But the key difference is practical: mebendazole has an established human safety profile from decades of approved use, giving doctors a framework for what to expect and what to monitor. Mebendazole is also poorly absorbed at standard doses, meaning most of it stays in the gut rather than entering the bloodstream, which has historically made it relatively low-risk.
Fenbendazole lacks that same body of human data. If someone is taking it, there is no sanctioned human formulation to reference, and clinicians have little guidance on how to evaluate potential interactions or side effects.
Australia’s Recent Scheduling Change
Australia took a notable regulatory step in 2025 by formally scheduling fenbendazole. Under the new rules, which took effect in October 2025, fenbendazole for human use falls under Schedule 4, meaning it requires a prescription. When used for animals, it remains under the less restrictive Schedule 5 category. This change was a direct response to growing public interest in using the veterinary product for unapproved human purposes. In the U.S., no equivalent reclassification has occurred, and the drug remains freely available as an animal product.
The Bottom Line on Access
You can walk into a farm supply store today and buy fenbendazole without showing ID, answering questions, or obtaining any kind of prescription. That accessibility sometimes creates the impression that the drug is safe for people, or at least benign. But OTC status for an animal drug reflects only that it’s considered safe enough for animals to use without veterinary oversight. It says nothing about human safety. The gap between “easy to buy” and “appropriate for human use” is significant, and right now, no regulatory body in the world has bridged it.